FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Lexicon Refiles NDA for Sotagliflozin

After receiving a 2019 complete response letter, Lexicon Pharmaceuticals resubmits its NDA for sotagliflozin oral tablets as an adjunct to insulin the...

latest-news-card-1
Biologics

Dj vu: Marks Overrides Reviewers on Duchenne Drug Again

CBER director Peter Marks again overrides his Centers review teams in approving a supplemental BLA that expands the approval and converts to full appr...

latest-news-card-1
Medical Devices

Zoll Recalls Ventilators Over Operator Guides

Zoll Medical recalls (Class 1) its Zoll 731 Ventilators and their operator and quick reference guides.

latest-news-card-1
Human Drugs

Clinical Hold Lifted on Huntingtons Drug

FDA lifts a partial clinical hold on PTC Therapeutics PTC518 for treating Huntingtons disease based on the agencys review of Phase 2 trial data (PIVOT...

latest-news-card-1
Human Drugs

FDA OKs Major Yescarta, Tecartus REMS Changes

FDA approves changes to the REMS for Kites lymphoma treatments Yescarta and Tecartus.

latest-news-card-1
Human Drugs

4 Observations in Dr. Reddys Inspection

FDA releases the form FDA-483 issued with four observations following an inspection at the Dr. Reddys active pharmaceutical ingredient manufacturing f...

latest-news-card-1

Inspection Delay, Denial, Limit, Refusal Guidance

FDA publishes a guidance describing the behaviors the agency sees as delaying, denying, limiting, or refusing a drug or device inspection.

latest-news-card-1
Biologics

FDA Abandoning Biosimilar Switching Studies

FDA issues a draft guidance indicating that it is moving away from recommending switching studies to support an interchangeability determination for b...

latest-news-card-1
Federal Register

20 No-Longer-Marketed ANDAs Withdrawn

Federal Register notice: FDA withdraws approval of 20 ANDAs from multiple applicants after they notified the agency that the drug products were no lon...

latest-news-card-1
Human Drugs

Jazz Tremor Drug Misses Primary Endpoint

Jazz Pharmaceuticals says data from its Phase 2b clinical trial evaluating the efficacy and safety of suvecaltamide in adult patients with essential t...